Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term administration & dosage. Found 208 abstracts

no pagination
Zhang Y, Zhao J, Li R, Lau WB, Yuan YX, Liang B, Li R, Gao EH, Koch WJ, Ma XL, Wang YJ. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. Am J Physiol Endocrinol Metab. 2015 Aug;309(3):E275-82.   PMCID: PMC4525114
Ali SM, Alpaugh RK, Downing SR, Stephens PJ, Yu JQ, Wu H, Buell JK, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M. Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. J Clin Oncol. 2014 Sep;32(25):e88-91.   PMCID: 4876358
Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2014 Aug 21;124(8):1259-65.   PMCID: Pmc4141515
Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20;32(12):1210-7.   PMCID: Pmc3986384
Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. Br J Haematol. 2014 Aug;166(4):514-20.
Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin Cancer Res. 2014 Sep 15;20(18):4747-57.   PMCID: 4377301
Jacobs JD, Hopper-Borge EA. Carotid artery infusions for pharmacokinetic and pharmacodynamic analysis of taxanes in mice. Journal of visualized experiments : JoVE. 2014 Oct 27;92(92):e51917.   PMCID: 4353391
Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, Benner RJ, Scranton JR, Olszanski AJ, Jassem J. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2014 Jul;32(19):2059-66.   PMCID: Pmc4067944
Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, Huang X, Valota O, Williams JA. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50.   PMCID: 4175044
Plimack ER, Desai JR, Issa JP, Jelinek J, Sharma P, Vence LM, Bassett RL, Ilagan JL, Papadopoulos NE, Hwu WJ. A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: Impact on DNA methylation and lymphocyte populations. Investigational New Drugs. 2014 Oct;32(5):969-75.   PMCID: 4171200
Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun 20;32(18):1895-901.   PMCID: PMC4050203
Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res. 2014 Jun;20(11):3023-32.   PMCID: Pmc4049169
Shen C, Chien CR, Geynisman DM, Smieliauskas F, Shih YC. A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):45-69.
Thomay AA, Nagorney DM, Cohen SJ, Sigurdson ER, Truty MJ, Burtness B, Hall MJ, Chun YS. Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer. J Gastrointest Surg. 2014 Jan;18(1):69-74.
Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2014 Jul;146(1):145-52.
Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. 2014 Jan;25(1):132-8.   PMCID: No NIH funds
von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25.   PMCID: Pmc4045341
Ma X, Xu RH, Roscoe F, Whitbeck JC, Eisenberg RJ, Cohen GH, Sigal LJ. The mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy. J Virol. 2013 Jun;87(12):7046-53.   PMCID: 3676127
Sterious S, Simhan J, Uzzo RG, Gershman B, Li T, Devarajan K, Canter D, Walton J, Fogg R, Ginzburg S, Corcoran A, Smaldone MC, Kutikov A. Familiarity and self-reported compliance with American Urological Association best practice recommendations for use of thromboembolic prophylaxis among American Urological Association members. J Urol. 2013 Sep;190(3):992-8.
Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer. 2012 Dec;43(4):562-9.   PMCID: 3400721
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term administration & dosage

administration & dosage Female drug therapy Middle Aged Male Aged therapeutic use adverse effects pathology Adult Antineoplastic Combined Chemotherapy Protocols metabolism Disease-Free Survival Treatment Outcome Kaplan-Meier Estimate 80 and over Aged Paclitaxel Neoplasm Staging mortality chemically induced Monoclonal Antibodies Drug Administration Schedule Monoclonal Antibodies-Humanized pharmacokinetics genetics methods Organoplatinum Compounds effects Lung Neoplasms Prognosis Tumor Biomarkers Maximum Tolerated Dose immunology analogs & derivatives Carboplatin Antineoplastic Agents drug effects adverse Neoplasms Insulin-Like Growth Factor I blood antagonists & inhibitors Neoplasm Drug Resistance Signal Transduction Biological Tumor Markers Recombinant Proteins therapy analysis Proportional Hazards Models Prospective Studies Inbred C57BL Mice Oxidative Stress Non-Small-Cell Lung Carcinoma prevention & control Neutropenia Polyethylene Glycols Oral Administration Young Adult Ovarian Neoplasms Colorectal Neoplasms Mice Doxorubicin Leukocyte Count Cost-Benefit Analysis diabetes Von Hippel-Lindau Tumor Suppressor Protein Pyrazines Guideline Adherence Myocardial Reperfusion Injury SCID Mice Ductal Carcinoma-Breast Cyclin-Dependent Kinase Inhibitor p27 B-Cell Lymphoma Hypoglycemic Agents treatment Internet Angiogenesis Inhibitors Ki-67 Antigen Melanoma DNA Methylation Fatigue Vascular Endothelial Growth Factor A Chemoradiotherapy Virion Survival Analysis Drug Industry Gene Expression Profiling Camptothecin Questionnaires surgery Urologic Surgical Procedures Cisplatin Drug Delivery Systems Transitional Cell Carcinoma Adiponectin Receptors Breast Neoplasms Hydroxamic Acids Superoxide Dismutase IGF Type 1 Receptor Local Neoplasm Recurrence Filgrastim Bortezomib Granulocyte Colony-Stimulating Factor Protective Agents Liver Neoplasms Taxoids Gastrointestinal Diseases dosage T-Lymphocyte Subsets Piperidines Cross-Sectional Studies Animal Models Cyclin-Dependent Kinase Inhibitor p21 chemotherapy Angiopoietin-2 Pyrroles ras Proteins Liver Intra-Arterial Infusions Imidazoles biosynthesis Phosphatidylinositol 3-Kinases Cytosol Myocardial Ischemia ErbB-2 Receptor Indazoles physiopathology Neoplastic Gene Expression Regulation Adenocarcinoma Bevacizumab Double-Blind Method Triple Negative Breast Neoplasms Immunoglobulin G Urinary Bladder Neoplasms reperfusion injury Lymph Nodes Practice Guidelines as Topic Retrospective Studies Kidney Neoplasms Hepatectomy Viral Antibodies Quinazolines non-squamous Adolescent Methotrexate Phytogenic Antineoplastic Agents Fluorouracil Bispecific Antibodies Venous Thromboembolism Rituximab
Last updated on Tuesday, August 04, 2020